Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis

Abstract excerpt

Clinical trials are underway for the treatment of tuberous sclerosis (TSC)-associated tumours using mTOR inhibitors. Here, we show that many of the earliest renal lesions from Tsc1+/- and Tsc2+/- mice do not exhibit mTOR activation, suggesting that pharmacological targeting of an alternative pathway may be necessary to prevent tumour formation. Patients with TSC often develop renal cysts and those with inherited...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic and Kidney Cyst Diseases
• Share to Renal and related cancers
• Share to Tuberous Sclerosis Complex Research